

The table below reports the number of target lesions per patient. 138 patients had target lesions at study baseline. The remaining patients (N=82) had no target lesions.

Table 27: Number of target lesions per patient

<b>Treatment</b>	<b>Placebo (44)</b>	<b>Olaparib BD (51)</b>	<b>Olaparib TDS (43)</b>	<b>Overall (138)</b>
<b>Number of target lesions</b>				
1	25 ( 57)	31 ( 61)	18 ( 42)	74 ( 54)
2	11 ( 25)	14 ( 27)	18 ( 42)	43 ( 31)
3	6 ( 14)	5 ( 10)	6 ( 14)	17 ( 12)
4	1 ( 2)	1 ( 2)	0 ( 0)	2 ( 1)
5	1 ( 2)	0 ( 0)	1 ( 2)	2 ( 1)

The table below reports the location, length and measurement method of all target lesions by treatment. The location details for the other are summarised in a separate table.

Table 28: Characteristics of all target lesions

<b>Treatment</b>	<b>Placebo (74)</b>	<b>Olaparib BD (78)</b>	<b>Olaparib TDS (77)</b>	<b>Overall (229)</b>
<b>Target lesion location</b>				
Bone	0 ( 0)	2 ( 3)	1 ( 1)	3 ( 1)
Brain	0 ( 0)	0 ( 0)	2 ( 3)	2 ( 1)
Liver	20 ( 27)	12 ( 15)	18 ( 23)	50 ( 22)
Lung	34 ( 46)	42 ( 54)	30 ( 39)	106 ( 46)
Lymph node	13 ( 18)	14 ( 18)	15 ( 19)	42 ( 18)
Other	7 ( 9)	8 ( 10)	11 ( 14)	26 ( 11)
<b>Lesion diameter (mm)</b>				
N	74	78	77	229
Mean (sd)	29 ( 17)	25 ( 14)	23 ( 10)	25 ( 14)
Range	11, 93	10, 76	10, 64	10, 93
<b>Method of measurement</b>				
Imaging	69 ( 93)	75 ( 96)	76 ( 99)	220 ( 96)
Caliper / ruler	5 ( 7)	3 ( 4)	1 ( 1)	9 ( 4)

The two target lesions located in the brain for the Olaparib treatment arm were both for TNO 014001.

Table 29: Locations of target lesions specified as other

Treatment	Placebo (7)	Olaparib BD (8)	Olaparib TDS (11)	Overall (26)
<b>Other specified lesion locations</b>				
Adrenal	5 ( 71)	7 ( 88)	6 ( 55)	18 ( 69)
Aortopulmonary window	0 ( 0)	0 ( 0)	1 ( 9)	1 ( 4)
Left apical pancoast	0 ( 0)	1 ( 13)	0 ( 0)	1 ( 4)
Left paracolic gutter	0 ( 0)	0 ( 0)	1 ( 9)	1 ( 4)
Left retroperitoneum	0 ( 0)	0 ( 0)	1 ( 9)	1 ( 4)
Mediastinum	1 ( 14)	0 ( 0)	0 ( 0)	1 ( 4)
Pancreatic tail	1 ( 14)	0 ( 0)	0 ( 0)	1 ( 4)
Right kidney	0 ( 0)	0 ( 0)	1 ( 9)	1 ( 4)
Spleen	0 ( 0)	0 ( 0)	1 ( 9)	1 ( 4)

The table below reports the number of non-target lesions per patient. 160 patients had non-target lesions at study baseline.

Table 30: Number of non-target lesions per patient

Treatment	Placebo (52)	Olaparib BD (54)	Olaparib TDS (54)	Overall (160)
N				
1	23 ( 44)	28 ( 52)	19 ( 35)	70 ( 44)
2	22 ( 42)	13 ( 24)	17 ( 31)	52 ( 33)
3	4 ( 8)	9 ( 17)	12 ( 22)	25 ( 16)
4	3 ( 6)	2 ( 4)	3 ( 6)	8 ( 5)
5	0 ( 0)	0 ( 0)	2 ( 4)	2 ( 1)
6	0 ( 0)	1 ( 2)	0 ( 0)	1 ( 1)
7	0 ( 0)	1 ( 2)	1 ( 2)	2 ( 1)

The table below reports the location of all non target lesions by treatment. The location details for the other are summarised in a separate table.

Table 31: Location of baseline non-target lesions

Treatment	Placebo (91)	Olaparib BD (102)	Olaparib TDS (118)	Overall (311)
<b>Non-target lesion location</b>				
Bone	23 ( 25)	19 ( 19)	21 ( 18)	63 ( 20)
Brain	1 ( 1)	0 ( 0)	1 ( 1)	2 ( 1)
Liver	12 ( 13)	13 ( 13)	14 ( 12)	39 ( 13)
Lung	25 ( 27)	29 ( 28)	32 ( 27)	86 ( 28)
Lymph node	20 ( 22)	36 ( 35)	34 ( 29)	90 ( 29)
Other	10 ( 11)	5 ( 5)	16 ( 14)	31 ( 10)

The TNOs for the 2 non-target lesions located in the brain were; TNO 031006 for the Placebo arm and TNO 014001 for the Olaparib TDS arm.

Table 32: Locations of non-target lesions specified as other

Treatment	Placebo (10)	Olaparib BD (5)	Olaparib TDS (16)	Overall (31)
<b>Other specified non-target lesion locations</b>				
Abnormal soft tissue fat in upper quadrant spleen, colon and pancreas	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Abnormal soft tissue left retroperitoneal fat	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Additional soft tissue in the subcarinal region	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Adrenal	2 ( 20)	2 ( 40)	2 ( 13)	6 ( 19)
Aorta pulmonary window - soft tissue	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Appearances in abdomen	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Appearances in throat	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Breast nodules	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Infiltrative ST mediastinum to Rt hilum	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Left Latissimus Dorsi	0 ( 0)	1 ( 20)	0 ( 0)	1 ( 3)
Mediastinum	0 ( 0)	1 ( 20)	0 ( 0)	1 ( 3)
Multiple sclerotic lesions	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Nodule in retroperitoneal fat	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Ovoid soft tissue density lying in the fat above right kidney	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Pericardial effusion	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Peritoneal	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Pleural effusion	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Prevascular	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Right para tracheal	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Right paratracheal - soft tissue	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Right paratracheal region	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Right posterior chest wall deposit	0 ( 0)	1 ( 20)	0 ( 0)	1 ( 3)
Subcutaneous nodules - abdomen	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Subcutaneous nodules - chest	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)
Superior hilar thickening	1 ( 10)	0 ( 0)	0 ( 0)	1 ( 3)
Supraclavicular fossae slight asymmetry with some impression of some residual abnormal soft tissue	0 ( 0)	0 ( 0)	1 ( 6)	1 ( 3)

Table 33: Table of numbers of patients with liver metastases

Treatment	Placebo (74)	Olaparib BD (73)	Olaparib TDS (73)	Overall (220)
<b>Liver metastases present at baseline</b>				
No	55 ( 74)	54 ( 74)	53 ( 73)	162 ( 74)
Yes	19 ( 26)	19 ( 26)	20 ( 27)	58 ( 26)